Dr. Jorge Agi, MD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Years since graduation
- 14
- In the NPI registry since
- 2023
- Medicare patients seen, 2024
- 256
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2023Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
FL license MFC1884 -
Ophthalmic Plastic and Reconstructive Surgery Physician
FL license 1884
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Tampa General Hospital Tampa, FL
Medical groups
- University Medical Service Association Inc (809 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 256
- Services billed
- 2,145
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 10-19 minutes | 88 | 70 |
| Established patient office or other outpatient visit, 20-29 minutes | 64 | 53 |
| Established patient office or other outpatient visit, 30-39 minutes | 26 | 25 |
| New patient office or other outpatient visit, 30-44 minutes | 24 | 24 |
| Exam of visual field with intermediate testing | 23 | 23 |
| New patient office or other outpatient visit, 15-29 minutes | 21 | 21 |
| Photography of content of eyes | 13 | 11 |
| Photography of the retina | 12 | 11 |
| Insertion of probe into nasal tear duct | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Erythromycin (erythromycin base) Other prescribers in Tampa, FL | 162 |
| Tobramycin-Dexamethasone (tobramycin/dexamethasone) Other prescribers in Tampa, FL | 59 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Tampa, FL | 49 |
| Moxifloxacin (moxifloxacin hcl) Other prescribers in Tampa, FL | 38 |
| Latanoprost Other prescribers in Tampa, FL | 20 |
| Prednisolone Acetate Other prescribers in Tampa, FL | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 9 payments worth $3,901 in total to this clinician.
| Immunocore Limited | $3,750 |
|---|---|
| Axogen | $85.78 |
| Medical Device Business Services, Inc. | $64.51 |
| Honoraria | $2,000 |
|---|---|
| Travel and Lodging | $1,665 |
| Food and Beverage | $236 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Immunocore Limited Oct 16, 2025 | Honoraria KIMMTRAK · Oncology | $2,000 |
| Immunocore Limited Sep 29, 2025 | Travel and Lodging KIMMTRAK · Oncology · travel to Donia Beach, FL · in-kind | $1,585 |
| Immunocore Limited Sep 26, 2025 | Travel and Lodging KIMMTRAK · Oncology · travel to Donia Beach, FL · in-kind | $80.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $104,090 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC ad…
Argenx US, Inc. - A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Imm…
Argenx US, Inc. - A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Acti…
Argenx US, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.